Motixafortide 99% Cas No.664334-36-5

Peb tshwj xeeb hauv kev muab siab -purity Motixafortide active pharmaceutical ingredient (API) hmoov, nrog rau cov khoom nruj me ntsis ua raws li kws tshuaj- cov qauv qib.

Peb nkag siab tag nrho cov kev cai nruj ntawm API cov saw hlau rau kev tshawb fawb tshuaj, kev tsim kho thiab tsim khoom. Yog li ntawd, peb muab cov kev xaiv ntim tau yooj yim txij li milligram mus rau kilogram kom muaj nuj nqis, muab kev txhawb nqa rau peb cov neeg siv khoom xav tau thoob plaws txhua theem txij thaum ntxov-theem R&D mus rau kev lag luam tsim khoom. Peb cia siab tias yuav txhawb nqa koj cov haujlwm nrog peb cov khoom API siab - zoo.

Motixafortide yog ib qho zoo heev thiab xaiv antagonist ntawm chemokine receptor CXCR4. Nws thawj pharmacological kev nqis tes ua pharmacological kev ua muaj xws li:

Thaiv CXCR4 / CXCL12 Signaling Axis: Qhov no yog nws cov txheej txheem tseem ceeb ntawm kev ua, ua tiav los ntawm kev tuav lub chaw receptor thiab kev sib tw inhibiting kev khi ntawm endogenous ligand CXCL12 (tseem hu ua SDF-1).

Mobilizing Hematopoietic Stem Cells: Los ntawm kev cuam tshuam cov anchorage mediated los ntawm CXCR4 / CXCL12, nws txhawb kev tso tawm ntawm hematopoietic qia thiab progenitor hlwb los ntawm cov pob txha pob txha stroma rau hauv peripheral ncig.

Immunomodulation thiab Synergistic Anti-mob nyhuv: Nws tuaj yeem ua rau muaj kev nkag mus ntawm lub cev tiv thaiv kab mob (xws li T hlwb thiab NK hlwb) rau hauv cov qog microenvironment qog microenvironment thiab tau pom muaj kev sib koom ua ke nrog qee yam tshuaj tiv thaiv kab mob (xws li, tiv thaiv -PD-1 antibodies).

Inducing Tumor Cell Apoptosis: Nws muaj qhov ncaj qha pro-apoptotic cuam tshuam rau qee hom mob qog noj ntshav uas nyob ntawm CXCR4 teeb liab rau kev ciaj sia.

Cov txheej txheem ntawm kev ua ntawm Motixafortide yog nyob ntawm nws qhov tshwj xeeb lub hom phiaj ntawm CXCR4 receptor:

Hauv stem cell mobilization:nws thaiv cov teeb liab uas CXCL12 "txheej txheem" ​​cov qia hlwb mus rau cov pob txha pob txha stromal hlwb, ua rau cov active "tshem tawm" ntawm qia hlwb mus rau hauv cov ntshav peripheral.

Hauv kev siv tshuaj tiv thaiv- mob qog noj ntshav, nws cov txheej txheem yog ntau-faceted:

● Kev cuam tshuam ntawm Tumor Sanctuary:Ntau cov qog nqaij hlav cancer (xws li, hauv ntau yam myeloma, leukemia) siv CXCR4 / CXCL12 axis rau hauv tsev los tiv thaiv microenvironments zoo li cov pob txha pob txha, evading chemotherapy. Motixafortide tuaj yeem hloov lawv los ntawm cov "sanctuaries," uas nthuav tawm lawv mus tua los ntawm cov tshuaj chemotherapeutic lossis lub cev tiv thaiv kab mob.

● Hloov Cov Tumor Microenvironment:Los ntawm kev hloov pauv kev lag luam thiab kev ua haujlwm ntawm lub cev tiv thaiv kab mob, nws tuaj yeem pab hloov "mob khaub thuas" mus rau "cov qog kub", ua kom lub cev tiv thaiv kab mob - tiv thaiv kab mob.

Raws li cov khoom siv tshuaj nquag (API), nws "kev ua tau zoo" yog hais txog nws cov dej num lom neeg, uas yog lub hauv paus rau kev tsim cov dej hauv qab hauv qab:

Muaj zog Stem Cell Mobilizer:Thaum ua ke nrog granulocyte colony-stimulating factor (G-CSF), nws ua rau kom cov qoob loo ntawm CD sau34+ qia hlwb piv rau G-CSF ib leeg, ua rau ntau tus neeg mob mus txog lawv cov hom phiaj sau hauv tsawg dua apheresis zaug.

Muaj peev xwm tiv thaiv -cancer Sensitizer:Preclinical thiab soj ntsuam kev tshawb fawb tau pom nws lub peev xwm los txhim kho kev ua tau zoo ntawm chemotherapy, tsom txoj kev kho, thiab immunotherapy.

Raws li cov txheej txheem tshuaj pharmacological saum toj no, Motixafortide API feem ntau yog siv rau hauv kev tshawb fawb, kev tsim kho, thiab kev tsim cov tshuaj hauv thaj chaw hauv qab no:

Stem Cell Transplantation:Nws yog FDA- pom zoo rau kev siv ua ke nrog G-CSF txhawm rau txhim kho hematopoietic qia hlwb mus rau cov ntshav peripheral rau kev sau thiab tom qab hloov pauv autologous hauv cov neeg mob uas muaj ntau yam myeloma. Qhov no yog nws thawj daim ntawv thov tsim.

Oncology Kev Kho Mob:Nws yog nyob rau hauv kev tshawb nrhiav dav dav rau kev siv cov tswv yim kho mob rau ntau yam kev ua phem, suav nrog:

Acute Myeloid Leukemia (AML):Txhawm rau tsim cov qog ntshav qog ntshav los ntawm cov pob txha pob txha, ua rau lawv muaj kev cuam tshuam rau kev siv tshuaj khomob.

Cov qog nqaij hlav:Xws li mob qog noj ntshav pancreatic thiab mob qog noj ntshav, txhawm rau cuam tshuam cov qog microenvironment thiab txhim kho kev nkag mus thiab kev ua tau zoo ntawm cov kev kho mob uas twb muaj lawm.

Combination Immunotherapy:Raws li kev sib koom ua ke rau kev tiv thaiv kab mob, nws lub hom phiaj kom kov yeej cov kab mob tiv thaiv kab mob ntawm cov qog thiab nce cov lus teb rau cov tshuaj tiv thaiv kab mob.

Cov ntaub ntawv saum toj no yog ua raws li kev tshawb fawb txog kev tshawb fawb thiab cov ntaub ntawv kho mob pej xeem thiab yog siv rau kev siv nkaus xwb. Cov khoom no yog ib qho Active Pharmaceutical Ingredient (API) npaj nruj heev rau kev siv los ntawm cov kws tshaj lij hauv kev tshawb fawb tshuaj, kev tsim kho, thiab kev tsim khoom. Nws yog txwv tsis pub siv ncaj qha rau tib neeg lossis kev tswj hwm raws li cov khoom siv tshuaj tiav.

Cim npe nrov: Motixafortide 99% CAS No.664334-36-5, Tuam Tshoj motixafortide 99% cas no.664334-36-5 manufacturers, lwm tus neeg, Hoobkas